Mark Adelsberg

Mark Adelsberg supports clients through data-driven analysis and economic insights that inform business decisions affected by federal and state policy.

He leverages his experience in Medicare policy, provider reimbursement, and alternative payment models to provide clients with detailed analytics, including impact and risk analysis, forecasting, and simulations.

Prior to joining Avalere, Mark was a manager of economic and regulatory affairs at the College of American Pathologists, where he provided expertise to physician members in the CPT/RUC code valuation process, Medicare coverage policy, physician-focused payment models, and quality measure development. Previously, as the senior director of health data at Strategic Health Care, he managed data analysis projects describing the impact of regulatory and legislative changes for a wide range of healthcare clients.

Mark has an MPP from the College of William and Mary and a BA in economics from Haverford College.

Authored Content

Oncology practices with a substantial proportion of Oncology Care Model (OCM) episodes in areas with high numbers of COVID-19 cases—such as Connecticut, Louisiana, Massachusetts, New Jersey, New York, and Pennsylvania—may face new challenges in containing total expenditure below target amounts.

Avalere analysis finds that new users account for a large share of Medicare spending on opthalmic medications.

Avalere’s findings were featured in the Journal of Parenteral and Enteral Nutrition.

New Avalere analysis finds that practices currently participating in the Oncology Care Model (OCM) would be more likely to receive a Novel Therapy Adjustment (NTA) in the newly proposed Oncology Care First (OCF) Model.

New analysis from Avalere finds the proposed case-mix adjustment for the radiation oncology model underestimates payments for prostate cancer .

Avalere experts recently presented “A Comprehensive Analysis of Influenza Vaccine Uptake in Medicare” at the National Adult and Influenza Immunization Summit in Atlanta, GA.

A new Avalere analysis finds that oncology practices participating in the Oncology Care Model (OCM) treated patients with 2–3% higher Medicare costs per episode, on average, than OCM prediction model estimates during the first two performance periods.

Pressure to lower costs will increase for OCM providers as CMS pushes to 2-sided risk.

New research from Avalere finds that the provision of pneumococcal conjugate vaccines increased immediately after ACIP’s 2014 recommendation to add the vaccine to the routine immunization schedule for older adults.